CDA Health subsidiary Burleigh Heads Cannabis (BHC) has reported a surge in demand following the Therapeutic Goods Administration’s decision to down schedule CBD late last year.
The company said while it will be months before products are approved as Schedule 3 (over-the-counter) medicines, “that didn’t stop Australians from going in droves and asking pharmacists for more information about low-dose cannabinoid oil products over the past month”.
Milan Tappoo, senior partner at The Infinity Group, which owns 53 pharmacies, said: “We witnessed a huge increase in demand and interest across all our stores since the TGA’s announcement.
“While there are no low-dose CBD medications currently registered, the news has raised awareness of medicinal cannabis and its therapeutic benefits. It’s driven people to their doctors to discuss prescription options instead and now we are dispensing medicinal cannabis daily.”
Before the TGA announcement, BHC had already registered more than a quarter of Australia’s pharmacies, with 325 registered doctors and thousands of active medical cannabis patients using its CanView platform.
CanView brings together pharmacists, doctors and patients and connects them with medicinal cannabis products from various suppliers. BHC stocks more than 80 products from local and international suppliers.
As a sign of the increased demand since, more than 21% of the 70,000-plus products shipped by BHC to Australian patients since its launch in June 2020 were from February 2021 alone.
It has achieved sales of more than A$10 million through CanView since launch.
General manager of CDA Health and BHC Rachael Cooney said: “If the initial response to the TGA announcement is anything to go by, then now is the time to be learning about the products ahead of further demand.
“We’re encouraging doctors and pharmacists to sign up for the free platform now, and to go through the training courses we have available before the first products hit the shelves.”